FDA's Arthritis Drugs Advisory Committee recommends Celebrex approval

Share this article:
The FDA's Arthritis Drugs Advisory Committee has voted to recommend approval of Pfizer's Celebrex for use in juvenile rheumatoid arthritis, despite long-term safety concerns. They recommended that, if approved, Pfizer continues to study long-term safety and establish a patient registry.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Legal/Regulatory

Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.